Aplastic Anemia

Aplastic anemia is a bone marrow failure syndrome tested on USMLE Step 1 through three consistent traps: students assume the marrow is hypercellular (it's hypocellular), apply ATG plus cyclosporine to every patient regardless of age or donor availability, and miss seronegative hepatitis as a trigger. The syndrome occurs when destruction or suppression of hematopoietic stem cells leads to pancytopenia — low RBCs, WBCs, and platelets simultaneously — and the bone marrow is replaced by fat.

The exam tests recognition of classic triggers (chloramphenicol, parvovirus B19, seronegative hepatitis, Fanconi anemia), interpretation of the marrow biopsy as hypocellular/fatty, and management selection based on patient-specific factors. Aplastic anemia mimics other causes of pancytopenia, so the exam includes a peripheral smear with no blasts (ruling out leukemia) as the key distinguishing clue.

For management: young patients with a matched sibling donor go straight to allogeneic stem cell transplant. ATG plus cyclosporine is for older patients or those without a matched donor. USMLE Step 1 tests whether you know when to transplant versus when to immunosuppress.

From real student decks

70%have cards covering this topic

49%have mature cards

Common misconceptions

Common mistake

Gap: Missing that seronegative hepatitis is a classic trigger for aplastic anemia appearing after apparent recovery

Hepatitis-associated aplastic anemia is a well-recognized entity that typically follows seronegative hepatitis (not hepatitis B or C) and can present weeks after apparent recovery from the hepatitis.

Seronegative hepatitis — meaning hepatitis that tests negative for hepatitis A, B, and C — is a well-established trigger for aplastic anemia that can appear weeks after the patient seems to have recovered from the liver illness. Students miss this because they assume viral hepatitis means hepatitis B or C, but those specific serotypes are not the culprits here. If a vignette describes a young patient with recent hepatitis of unclear etiology who now has pancytopenia, seronegative hepatitis-associated aplastic anemia should be on your differential.

Common mistake

Wrong: ATG plus cyclosporine is the preferred treatment for all patients with aplastic anemia.

Right: Young patients with a matched sibling donor should receive allogeneic stem cell transplant (curative); ATG plus cyclosporine is reserved for older patients or those without a matched donor.

ATG plus cyclosporine is immunosuppressive therapy, which is effective but not curative — it reduces immune destruction of stem cells but does not replace them. For young patients who have a matched sibling donor, allogeneic stem cell transplant offers a true cure and is the preferred first-line treatment. ATG plus cyclosporine is reserved for patients who are older, lack a matched donor, or are not transplant candidates. Applying immunosuppression universally ignores the curative option available to the subset of patients most likely to tolerate and benefit from transplant.

Common mistake

Wrong: Aplastic anemia presents with a hypercellular bone marrow due to compensatory hematopoiesis.

Right: Aplastic anemia presents with a hypocellular (fatty) bone marrow due to destruction or suppression of hematopoietic stem cells.

The marrow is hypocellular in aplastic anemia because the hematopoietic stem cells are destroyed or suppressed — there is nothing left to proliferate and create a compensatory response. This is the opposite of what happens in hemolytic anemias or myelophthisic processes, where the marrow often ramps up. On biopsy, you see fat cells replacing the normal hematopoietic architecture. If you see 'hypercellular marrow' in an answer choice for aplastic anemia, it is wrong — that finding should instead point you toward myeloproliferative disorders or reactive states.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Recognize the defining marrow and blood findings of aplastic anemia: pancytopenia on CBC with a hypocellular (fatty) bone marrow biopsy and no increase in blasts.
Identify classic causes of aplastic anemia, including idiopathic (most common), drugs like chloramphenicol and chemotherapy, viruses like parvovirus B19 and seronegative hepatitis, and the inherited form Fanconi anemia.
Choose the correct management strategy based on patient profile: allogeneic stem cell transplant for young patients with a matched sibling donor, ATG plus cyclosporine for older patients or those without a matched donor, and supportive care (transfusions, growth factors) as a bridge.

Can you avoid these mistakes?

A 19-year-old presents with fatigue, easy bruising, and frequent infections three weeks after recovering from a hepatitis illness that tested negative for hepatitis A, B, and C. CBC shows pancytopenia and bone marrow biopsy shows a hypocellular, fatty marrow with no blasts. What is the most likely diagnosis, and what triggered it?

A 24-year-old with newly diagnosed severe aplastic anemia has a healthy HLA-matched sibling willing to donate. An older patient in the same clinic has the same diagnosis but no matched donor. How does treatment differ between these two patients, and why?

On a bone marrow biopsy report for a patient with pancytopenia, the pathologist describes 'replacement of hematopoietic tissue by adipocytes with less than 10% cellularity.' Is this finding consistent with aplastic anemia or against it? What would you expect if this were acute leukemia instead?

A patient develops aplastic anemia after a course of chloramphenicol for a serious infection. A student argues this was predictable and dose-dependent. What is wrong with that model, and what is the correct mechanism by which chloramphenicol causes aplastic anemia?

Aplastic Anemia

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics